Japan's Cost Effectiveness Assessment Needs Change: EFPIA
CAR-Ts Under Early Scrutiny
Executive Summary
European industry federation says first practical application of Japan’s cost effectiveness assessment system has highlighted a number of problems for both the scheme and its members, and calls for changes.
You may also be interested in...
Japan Pricing Environment ‘Highly Unpredictable’: PhRMA
US research-based association says move to annual drug repricing undermines country’s recent efforts to support innovation and again calls for inclusive discussions around broad health system reforms to create funding headroom.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.